Endocrinol Metab.  2020 Jun;35(2):288-289. 10.3803/EnM.2020.35.2.288.

Association of Serum Progranulin Levels with Progression of Papillary Thyroid Cancer

• Kim WG

• KMID: 2503258
• DOI: http://doi.org/10.3803/EnM.2020.35.2.288

Reference

1. Schmid D, Ricci C, Behrens G, Leitzmann MF. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. Obes Rev. 2015; 16:1042–54.

2. Kitahara CM, McCullough ML, Franceschi S, Rinaldi S, Wolk A, Neta G, et al. Anthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies. Thyroid. 2016; 26:306–18.

3. Kim WG, Cheng SY. Mechanisms linking obesity and thyroid cancer development and progression in mouse models. Horm Cancer. 2018; 9:108–16.

4. Marcello MA, Cunha LL, Batista FA, Ward LS. Obesity and thyroid cancer. Endocr Relat Cancer. 2014; 21:T255–71.

5. Kwon H, Park SE, Yun JS, Park CY. Serum Adiponectin and progranulin level in patients with benign thyroid nodule or papillary thyroid cancer. Endocrinol Metab (Seoul). 2020; 35:396–406.

6. Pazaitou-Panayiotou K, Panagiotou G, Polyzos SA, Mantzoros CS. Serum adiponectin and insulin-like growth factor 1 in predominantly female patients with thyroid cancer: association with the histologic characteristics of the tumor. Endocr Pract. 2016; 22:68–75.

7. Cheng SP, Liu CL, Hsu YC, Chang YC, Huang SY, Lee JJ. Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma. Cell Biochem Biophys. 2013; 65:203–10.

8. Abella V, Pino J, Scotece M, Conde J, Lago F, Gonzalez-Gay MA, et al. Progranulin as a biomarker and potential therapeutic agent. Drug Discov Today. 2017; 22:1557–64.

9. De Muynck L, Van Damme P. Cellular effects of progranulin in health and disease. J Mol Neurosci. 2011; 45:549–60.

10. Neill T, Buraschi S, Goyal A, Sharpe C, Natkanski E, Schaefer L, et al. EphA2 is a functional receptor for the growth factor progranulin. J Cell Biol. 2016; 215:687–703.